Maintenance or Consolidation Therapy in Advanced Ovarian Cancer

Abstract

Most patients with advanced epithelial ovarian cancer (EOC) achieve a clinical complete response (CR) or have no clinical evidence of disease after aggressive cytoreductive surgery and 6 cycles of platinum-/taxane-based chemotherapy. From the reported randomized trials using different durations or different cycles of chemotherapy, none of these showed improvement in survival beyond 6 cycles. Data from the literature do not support a relationship between the number of cycles and response or between the cumulative dose and response. In addition, no benefit in survival was detected with high-dose and intensity chemotherapy administered for a short time compared with standard-dose chemotherapy given for a longer time. However, statistically significant differences in progression-free survival were found in patients who achieved a clinically defined CR to a platinum (CDDP)-/paclitaxel-based chemotherapy and who continued single-agent paclitaxel for an extended time period. Notably, this randomized trial most likely did not offer any survival advantage, as it was closed prematurely by the Data Safety Monitoring Committee in accordance with the guidelines planned for interim analysis of primary end-points.

Serum CA-125 Level after 6 Cycles of Primary Adjuvant Chemotherapy Is a Useful Prognostic Factor for Complete Responders’ Survival in Patients with Advanced Epithelial Ovarian Cancer

“…Although the number of chemotherapy cycles had no affect on survival in the current study (table 2) and the role of consolidation chemotherapy is controversial in complete responders with epithelial ovarian cancer who received primary adjuvant chemotherapy [12,13], the consolidation chemotherapy was considered to affect the association between serum CA-125 levels and survival in the current study. Thus, we performed a subanalysis of survival influenced by serum CA-125 levels according to cycles of chemotherapy.…”

Adverse reaction of a combined treatment for unresectable liver cancer

“…Clinical remission rate is defined as CR+PR, clinical effective rate is defined as CR+PR+MR, and clinical response rate is defined as CR+PR+MR+SD. Adverse reactions are evaluated on the basis of WHO grading criteria for acute and subacute toxicity of antitumor agents [15,16].…”

Prevention strategies for ovarian cancer

“…Die Antikörper Abagovomab und Beva cizumab sowie die Signaltransduktionsin hibitoren Lonafarnib, Pazopanib und Su nitinib sind (nicht vollständig gelistete) Beispiele [125,126,127,128,129,130]. Im Gegensatz zur konventionellen Chemo therapie sind Antikörper und "small mo lecules" mehr geeignet, im Sinne einer Er haltungstherapie auch längerfristig appli ziert zu werden [131]. Die Ergebnisse ak tueller Studien als auch zukünftiger Stu dien mit weiteren Molekülen müssen zeigen, welches therapeutische Potenzi al die Substanzen sowohl in der Thera pie als auch im Rahmen der Tertiärprä vention haben.…”